These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24055214)

  • 1. Translational PET imaging research.
    Hargreaves RJ; Rabiner EA
    Neurobiol Dis; 2014 Jan; 61():32-8. PubMed ID: 24055214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography in CNS drug discovery and drug monitoring.
    Piel M; Vernaleken I; Rösch F
    J Med Chem; 2014 Nov; 57(22):9232-58. PubMed ID: 25144329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging in Central Nervous System Drug Discovery.
    Gunn RN; Rabiner EA
    Semin Nucl Med; 2017 Jan; 47(1):89-98. PubMed ID: 27987561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging in drug development.
    Nairne J; Iveson PB; Meijer A
    Prog Med Chem; 2015; 54():231-80. PubMed ID: 25727706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of molecular imaging in drug discovery and development.
    Hargreaves RJ
    Clin Pharmacol Ther; 2008 Feb; 83(2):349-53. PubMed ID: 18167503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approach.
    Preskorn SH
    J Psychiatr Pract; 2015 Jan; 21(1):60-6. PubMed ID: 25603452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application of pre-clinical PET imaging for drug development].
    Tsukada H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):231-7. PubMed ID: 22256612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomographic imaging in drug discovery.
    Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
    Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains.
    de Mooij-van Malsen AJ; Pjetri E; Kas MJ
    Eur J Pharmacol; 2015 Apr; 753():135-9. PubMed ID: 25107283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From genes to therapeutic targets for psychiatric disorders - what to expect?
    Muglia P
    Curr Opin Pharmacol; 2011 Oct; 11(5):563-71. PubMed ID: 21893430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches in psychiatric drug development.
    van der Doef TF; Zaragoza Domingo S; Jacobs GE; Drevets WC; Marston HM; Nathan PJ; Tome MB; Tamminga CA; van Gerven JMA; Kas MJH
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):983-993. PubMed ID: 30056086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of PET data in CNS drug discovery and development.
    Varnäs K; Varrone A; Farde L
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):267-79. PubMed ID: 23660778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
    Burns HD; Van Laere K; Sanabria-Bohórquez S; Hamill TG; Bormans G; Eng WS; Gibson R; Ryan C; Connolly B; Patel S; Krause S; Vanko A; Van Hecken A; Dupont P; De Lepeleire I; Rothenberg P; Stoch SA; Cote J; Hagmann WK; Jewell JP; Lin LS; Liu P; Goulet MT; Gottesdiener K; Wagner JA; de Hoon J; Mortelmans L; Fong TM; Hargreaves RJ
    Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9800-5. PubMed ID: 17535893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
    Slobbe P; Poot AJ; Windhorst AD; van Dongen GA
    Drug Discov Today; 2012 Nov; 17(21-22):1175-87. PubMed ID: 22766374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.
    Brooks DJ
    NeuroRx; 2005 Apr; 2(2):226-36. PubMed ID: 15897947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of imaging in proof of concept for CNS drug discovery and development.
    Wong DF; Tauscher J; Gründer G
    Neuropsychopharmacology; 2009 Jan; 34(1):187-203. PubMed ID: 18843264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.